Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Recombinant growth hormone (rhGH) treatment is widely used in France to normalize height
during childhood and final height in children born small for gestational age (SGA). Because
rhGH has been associated with increased insulin levels and insulin resistance, concern has
been expressed regarding the late consequences of rhGH treatment on risk factors for diabetes
mellitus type II and metabolic syndrome, especially in possibly predisposed subjects as SGA
children.